

Puerarin inhibits apoptosis and inflammation in myocardial cells via PPAR α expression in rats with chronic heart failure

LE HE^{1*}, TONG WANG^{2*}, BING-WEI CHEN¹, FENG-MIN LU¹ and JING XU¹

¹Department of Cardiology, Tianjin Chest Hospital, Tianjin 300222; ²Department of Endocrinology, Tianjin Yellow River Hospital, Tianjin 300110, P.R. China

Received October 10, 2018; Accepted July 12, 2019

DOI: 10.3892/etm.2019.7984

Abstract. Chronic heart failure affects myocardial energy metabolism and cardiac function. Puerarin has been reported to improve cardiac function through regulation of energy metabolism in mice with myocardial infarction. The aim of the current study was to determine whether puerarin can improve body weight and reduce inflammation and apoptosis in rats with chronic heart failure. Rats were divided into three groups: Puerarin, PBS and sham group. Transverse aortic constriction was performed to induce chronic heart failure in the puerarin and PBS groups. Cardiac function, apoptosis and inflammation were evaluated following a 4-week treatment in rats with chronic heart failure. The results demonstrated that puerarin significantly increased the survival rate of rats and improved cardiac function compared with the PBS group. In addition, puerarin decreased lactate dehydrogenase and succinate dehydrogenase activity compared with the PBS group. Puerarin treatment increased the expression levels of glucose transporter type 4 and decreased the expression levels of CD36. Additionally, puerarin decreased the levels of inflammatory factors, including tumor necrosis factor α , interleukin (IL)-1 β and IL-6 in serum and myocardial tissue compared with the PBS group. Puerarin upregulated peroxisome proliferator-activated receptor α (PPAR α) and its downstream target genes nuclear respiratory factor 1, FOS proto-oncogene, YY1 transcription factor, acetyl-coenzyme A carboxylase α , Fas cell surface death receptor, L-type pyruvate kinase and acetyl-coenzyme A dehydrogenase medium chain in myocardial cells from rats with chronic heart failure. These results demonstrated that puerarin inhibited apoptosis and inflammation in myocardial cells via the PPAR α pathway.

In conclusion, the present study indicated that puerarin may exhibit antiapoptotic and anti-inflammatory activity through the PPAR α pathway in rats with chronic heart failure.

Introduction

Chronic heart failure is a complex disease caused by structural abnormalities, functional disorders, metabolic disturbance and/or drug stimulation (1-4). Chronic heart failure is the ultimate clinical manifestation of various cardiovascular and inflammatory diseases (5-7). Reports have indicated that chronic heart failure is one of the leading causes of disability and mortality in patients with heart disease worldwide (8-13). Chronic heart failure impairs myocardial energy metabolism, which leads to cardiac dysfunction and damages the circulation (14-16). Despite great advances in prevention and treatment of cardiovascular diseases in current medicine, chronic heart failure remains a therapeutic challenge as no effective treatments are available yet, with the exception of orthotopic heart transplantation (17-19).

Puerarin, which is extracted from *P. montana* var. *lobata*, which exhibits therapeutic efficacy for a range of human diseases (20-22). Duan *et al* (23) demonstrated that puerarin may improve heart function and increase left ventricular ejection fraction. He *et al* (24) reported that puerarin promotes angiogenic signaling, improved myocardial microcirculation and downregulated the endothelin system, which results in a reversal of aberrant SERCA2a and phospholamban expression. In addition, puerarin has multiple therapeutic effects for neurological dysfunction and inflammation (25). A previous study has provided compelling evidence that puerarin serves a role in inhibiting myocyte loss during heart failure partly through ferroptosis mitigation, which suggests a new mechanism for puerarin as a potential therapeutic agent for heart failure (26). However, the antiapoptotic and anti-inflammatory effects of puerarin on myocardial cells in patients with chronic heart failure are not well understood.

A previous study demonstrated that peroxisome proliferator-activated receptor α (PPAR α) may be involved in the apoptosis of myocardial tissue in chronic heart failure (27). In addition, puerarin may improve the clinical heart function, increase the left ventricular ejection and decrease the level of oxidized low-density lipoprotein (23). In the present study, the antiapoptotic and anti-inflammatory efficacy of puerarin was

Correspondence to: Professor Jing Xu, Department of Cardiology, Tianjin Chest Hospital, 93 Jizhao Road, Jinnan, Tianjin 300222, P.R. China
E-mail: jingxu188788@163.com

*Contributed equally

Key words: puerarin, chronic heart failure, apoptosis, inflammation, peroxisome proliferator-activated receptor α

investigated in rats with chronic heart failure. The potential mechanism of puerarin activity in myocardial cells from rats with chronic heart failure was also explored.

Materials and methods

Animals. A total of 30 male Sprague Dawley rats (age, 8-10 weeks; weight, 180-210 g) were purchased from the Experimental Animal Center of Tianjin University. The rats were housed at 24-26°C, 50% humidity with a 12-h light/dark cycle and *ad libitum* access to food and water. The experiments performed in this study were approved by the Animal Ethics Committee of Tianjin Chest Hospital (Tianjin, China). Rats were anaesthetized by intraperitoneal injection of pentobarbital (35 mg/kg), and chronic heart failure model was established as previously described (28). Following a 1-week adaptation period, the rats were randomly divided into three groups: PBS, puerarin and sham group (subjected to surgery without traverse aortic constriction) (n=10 rats/group). Rats with chronic heart failure received an intraperitoneal injection of puerarin (60 mg/kg; 99.0% purity; Beijing Saisheng Pharmaceutical Co., Ltd.) (29) or an equal volume of PBS (Sigma-Aldrich; Merck KGaA) once a day for 4 weeks. During the same 4-week period, rats in the sham group did not receive any treatments. Humane end points of experimental rats were set according to the OECD Guidance Document on the Recognition, Assessment, and Use of Clinical Signs as Humane End points for Experimental Animals Used in Safety Evaluation (30). Body weight was recorded for each rat on day 30 after treatment. Animals exhibiting signs of humane endpoints were sacrificed.

Cell culture. Myocardial cells were isolated from the rats in each group as described previously (31). Briefly, rats were decapitated after anesthesia (thiopental, 30 mg/kg IV) on day 30. The hearts were removed and placed into a plate using sterile scissors. Myocardial tissues were isolated and settled in Hank's Balanced Salt Solution (Gibco; Thermo Fisher Scientific, Inc.). Myocardial tissues were mechanically stirred and trypsinized with 0.5% trypsin at 37°C for 10 min, followed by centrifugation (6,000 x g for 15 min at 4°C) and suspension with DMEM (Gibco, Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco, Thermo Fisher Scientific, Inc.). Following cell attachment, the medium was replaced with DMEM supplemented with 0.5 mM glutamine, 100 U/ml penicillin, and 100 μ g/ml streptomycin (all from Gibco; Thermo Fisher Scientific, Inc.). Myocardial cells were cultured for three days at 37°C in a 5% CO₂ incubator. Following culture, the cells were treated with puerarin (2 mmol/l) or PBS for 12 h at 37°C prior to further analysis.

Knockdown of PPAR α . Transient knockdown of PPAR α was performed using the TransIT-X2 Dynamic Delivery System (Mirus Bio, LLC). In brief, myocardial cells (1x10⁵ cells/well) were plated in six-well plates and cultured for 12 h at 37°C. Following incubation, 25 mM PPAR α siRNA (si-PPAR α) or siRNA-negative control (si-NC; both supplied by Shanghai GenePharma Co., Ltd.) were transfected into myocardial cells using TransIT-X2 reagent (25 μ l) according to the manufacturer's instructions. The sequences of siRNAs were as follow:

si-PPAR α sense, 5'-AGAGCUACUUUUGUCCGATT-3' and antisense, 5'-UCCGACAAAAGUUUCCACUCG-3'; si-NC sense, 5'-UUCUCGAACGUGUCACGUTT-3' and antisense, 5'-ACGUGACACGUUCGGAGAATT-3'. Following incubation for 72 h, the expression of PPAR α in myocardial cells was analyzed using western blotting. Subsequently, PPAR α -knockdown myocardial cells were treated with puerarin (2 mmol/l) for 12 h at 37°C for further analysis.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay. Apoptotic rates of myocardial tissue or myocardial cells were analyzed using TUNEL assay (DeadEnd™ Colorimetric TUNEL System; Promega Corporation) according to the manufacturer's instructions. For myocardial tissues, tissues were fixed with 5% paraformaldehyde for 12 h at room temperature. 5- μ m-thick sections were fixed with 4% paraformaldehyde for 30 min at 37°C and dehydrated in gradient concentrations of ethanol. Tissue sections or myocardial cells (1x10⁴ cells/well) were incubated with TUNEL reagent for 30 min at 37°C. Cells were washed with PBS three times for 5 min at 37°C, followed by incubation with 5% DAPI (Sigma-Aldrich; Merck KGaA) for 15 min at 37°C. Images were captured using a ZEISS LSM 510 confocal microscope using 488 nm excitation fixed in Antifade Mounting Medium. The apoptotic rate was calculated using the Developer XD 1.2 software (Definiens AG).

ELISA. A total of 2 ml peripheral venous blood was obtained from experimental rats after 4 weeks of treatment. Serum was obtained following centrifugation (6,000 x g; 15 min at 4°C). C reactive protein (CRP; cat. no. MCRP00; Bio-Rad Laboratories, Inc.), TNF- α (cat. no. RTA00; Bio-Rad Laboratories, Inc.), IL-6 (cat. no. R6000B; Bio-Rad Laboratories, Inc.), IL-1 β (cat. no. DY501; Bio-Rad Laboratories, Inc.), brain natriuretic peptide (BNP; cat. no. MA134237; Thermo Fisher Scientific, Inc.), creatinine (cat. no. KGE005; R&D Systems, Inc.) and troponin T (cat. no. MAB1874; R&D Systems, Inc.) levels were analyzed using ELISA kits according to the manufacturers' instructions.

Determination of cardiac function. Following 4 weeks of treatment, the rats were anesthetized by intraperitoneal injection of pentobarbital (35 mg/kg). Ejection fraction (EF), heart rate (HR), fractional shortening (FS) and cardiac output (CO) in experimental rats were measured using a Vivid I ultrasound (GE Healthcare) equipped with a 12-MHz linear transducer.

Determination of lactate dehydrogenase (LDH) and succinate dehydrogenase (SDH) in serum. Serum was separated from peripheral venous blood as described above. LDH (cat. no. 10127230001; Roche Applied Science) and SDH (cat. no. 10109339001; Roche Applied Science) levels were measured using ELISA kits according to the manufacturer's instructions as previously described (32).

Immunohistochemistry. Myocardial tissues from the experimental rats were fixed with 10% formaldehyde for 1 h at room temperature, embedded in paraffin and cut into 4- μ m-thick sections. Antigen retrieval was performed using eBioscience™

Table I. Primers used for reverse transcription-quantitative PCR.

Gene name	Primer sequence (5'→3')	
	Forward	Reverse
Nrf1	ATGGCCCAAACCATCACCGGCAGCA	ATGTGCCAGGATCCAGTTTAG
Fos	TTGCTGCATAAAGTTTGTGATACAG	AGGAAAAGGCATCAGAGAAGTAGC
Yy1	GAAGCCCTTTCAGTGCACGTT	ACATAGGGCCTGTCTCCGGTAT
ACC1	CCCAATATTTATCATGAGACTTGCA	CAACATTTGAATGAAGTCCACG
FAS	ATTGCTCAACAACCATGCTG	CCAATCCCTTGGAGTTGATG
L-PK	GGAAGAAGACCCACAGGAAGCAATA	GAGAAGCCTCAAGGTTATGGATG
MCAD	TTGGTGACGGAGCTGGTTTCA	CATTGCCATTTACGCCAGCA
β-actin	CGGAGTCAACGGATTTGGTC	AGCCTTCTCCATGGTCGTGA

Nrf 1, nuclear respiratory factor 1; Fos, FOS proto-oncogene; Yy1, YY1 transcription factor; ACC1, acetyl-coenzyme A carboxylase α ; FAS, Fas cell surface death receptor; L-PK, L-type pyruvate kinase; MCAD, acetyl-coenzyme A dehydrogenase medium chain.

IHC Antigen Retrieval Solution (cat no. 00-4955-58; Invitrogen; Thermo Fisher Scientific, Inc.). Sections were washed with PBS with Tween-20 (PBST; Sigma-Aldrich; Merck KGaA), blocked with 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA) for 2 h at room temperature and incubated with rabbit anti-rat glucose transporter type 4 (GLUT4; 1:1,000; cat. no. ab33780; Abcam), CD36 (1:1,000; cat. no. ab64014; Abcam), tumor necrosis factor α (TNF- α ; 1:1,000; cat. no. ab6671; Abcam), interleukin (IL)-1 β (1:1,000; cat. no. ab200478; Abcam) and IL-6 (1:1,000; cat. no. ab7737; Abcam) for 2 h at 37°C. Following incubation, sections were washed with PBST three times and incubated with Alexa Fluor 488-labeled goat anti-rabbit secondary antibody (1:2,000; cat. no. ab150077; Abcam) for 2 h at 37°C. A diaminobenzidine staining system (3,3'-diaminobenzidine; Sigma-Aldrich; Merck KGaA) was used to detect target protein expression using a LSM-780 confocal microscope (Zeiss AG) according to manufacturer's protocol. Cell counting was performed in six randomly selected fields using Image Pro Analyzer software (version 7.0.0.951; MediaCybernetics) and analyzed using LAS AF software (version 2.0; Leica Microsystems, Inc.).

Reverse transcription-quantitative PCR (RT-qPCR). Myocardial cells were lysed and total RNA was extracted using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions. Total RNA was quantified with NanoDrop™ (NanoDrop Technologies; Thermo Fisher Scientific, Inc.). RNA (1 μ g) was reverse-transcribed using the cDNA Reverse Transcription kit (Takara Bio, Inc.) according to the manufacturer's protocol. qPCR was performed using an Applied Biosystems 7900HT Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) and Premix Ex Taq™ (Probe qPCR, Takara Biotechnology Co., Ltd.). Forward and reverse primers were synthesized by Thermo Fisher Scientific, Inc. and are listed in Table I. The following thermocycling conditions were used: Initial denaturation at 94°C for 2 min; followed by 45 cycles of 95°C for 30 sec, 57.5°C for 30 sec and 72°C for 60 sec; and final extension at 72°C for 10 min. Relative mRNA expression levels were calculated

using the $2^{-\Delta\Delta C_q}$ method (25). The results were normalized to β -actin.

Western blotting. The treated myocardial cells (1×10^8 cells/well) were lysed using RIPA lysis buffer (Thermo Fisher Scientific, Inc.). Protein concentration was measured using a BCA protein assay kit (Thermo Fisher Scientific, Inc.), and 10 μ g of proteins were separated using SDS-PAGE (12% gel). Protein was transferred onto a polyvinylidene fluoride membrane (EMD Millipore). Following blocking with 5% bovine serum albumin (BSA; Sigma-Aldrich; Merck KGaA) for 2 h at 37°C, the membranes were incubated with the following primary antibodies: TNF- α (1:1,000; cat. no. ab6671; Abcam), IL-1 β (1:1,000; cat. no. ab200478; Abcam), IL-6 (1:1,000; cat. no. ab7737; Abcam), nuclear respiratory factor 1 (Nrf1; 1:1,000; cat. no. ab175932; Abcam), FOS proto-oncogene (Fos; 1:1,000; cat. no. ab208942; Abcam), YY1 transcription factor (Yy1; 1:1,000; cat. no. ab109237; Abcam), acetyl-coenzyme A carboxylase α (ACC1; 1:1,000; cat. no. ab45174; Abcam), Fas cell surface death receptor (FAS; 1:1,000; cat. no. ab15285; Abcam), L-type pyruvate kinase (L-PK; 1:1,000; cat. no. ab202468; Abcam), acetyl-coenzyme A dehydrogenase medium chain (MCAD; 1:1,000; cat. no. ab92461; Abcam) and β -actin (1:2,000; cat. no. ab8226; Abcam) for 12 h at 4°C. Following three washes with PBS, the membranes were incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin G antibody (1:2,000; cat. no. PV-6001; OriGene Technologies, Inc.) for 24 h at 4°C. The membranes were washed with PBS and visualized with ECL Western blotting detection reagents (GE Healthcare). The band intensities were analyzed using ImageJ software 2.0 (National Institutes of Health).

Statistical analysis. Data are presented as the mean \pm SD. SPSS 19.0 software (IBM Corp.) was used for statistical analysis. The experiments were performed at least three times. Student's t-test was used for comparisons between two groups and one-way analysis of variance followed by Tukey post hoc test was used to evaluate the differences for multiple comparisons. $P < 0.05$ was considered to indicate a statistically significant difference.




Figure 1. Puerarin improves body weight and cardiac function and increases survival rate of rats with chronic heart failure. (A) Effects of puerarin on body weight of rats. Effects of puerarin on (B) FS, (C) LVEF, (D) CO and (E) HR. (F) Effects of puerarin on the survival rate of rats with chronic heart failure. *P<0.05 and **P<0.01 vs. PBS. FS, fractional shortening; LVEF, left ventricular ejection fraction; CO, cardiac output; HR, heart rate; ns, not significant.

Results

Puerarin improves cardiac function and increases survival rates in rats with chronic heart failure. The effects of puerarin on body weight, cardiac function and survival rate were analyzed in rat models of chronic heart failure. Body weight was significantly increased in the puerarin treatment group compared with the PBS group 30 days after treatment (P<0.05; Fig. 1A). Puerarin treatment significantly improved cardiac function, as indicated by increased FS, LVEF, CO and HR compared with the PBS group (all P<0.01; Fig. 1B-E, P<0.01). Puerarin treatment significantly increased the survival rate of rats compared with the PBS group (Fig. 1F, P<0.01). These results indicated that puerarin may improve cardiac function and survival rate of rats with chronic heart failure.

Puerarin decreases LDH and SDH levels in rats with chronic heart failure. The effects of puerarin on LDH and SDH levels were analyzed in serum of a rat chronic heart failure models. The results demonstrated that serum LDH (P<0.05) and SDH (P<0.01) levels were significantly lower in the puerarin-treated group compared with the PBS group (Fig. 2). These results indicated that puerarin may ameliorate chronic heart failure by decreasing LDH and SDH levels.

Puerarin inhibits myocardial apoptosis and inflammation in rats with chronic heart failure. The antiapoptotic and anti-inflammatory effects of puerarin in myocardial tissues were analyzed in a rat chronic heart failure model. The administration of puerarin decreased the number of TUNEL-positive cells in myocardial tissue compared with the PBS group (Fig. 3A, P<0.01). In addition, puerarin treatment increased the expression of GLUT4 and decreased the expression of CD36 compared with the PBS group (Fig. 3B, P<0.01). Of note, compared with the PBS group, the puerarin-treated group exhibited decreased serum levels of BNP, CRP, troponin T and creatinine (Fig. 3C-E, P<0.05 and P<0.01). These results indicated that puerarin may have




Figure 2. Puerarin decreases LDH and SDH levels in rats with chronic heart failure. *P<0.05 and **P<0.01 vs. PBS. LDH, lactate dehydrogenase; SDH, succinate dehydrogenase; ns, not significant.

antiapoptotic and anti-inflammatory efficacy in rats with chronic heart failure.

Puerarin decreases expression levels of inflammatory markers in a rat chronic heart failure model. Effects of puerarin on inflammatory markers were analyzed in rats with chronic heart failure. Compared with the PBS group, puerarin treatment decreased serum levels of TNF- α , IL-1 β and IL-6 in rats with chronic heart failure (Fig. 4A, P<0.01). No significant differences were observed between the puerarin and sham groups following 4-week treatment. Immunohistochemistry demonstrated that puerarin decreased TNF- α , IL-1 β and IL-6 expression levels in myocardial tissue in rats with chronic heart failure compared with the PBS group (Fig. 4B, P<0.01). The results indicated that puerarin may effectively inhibit inflammatory markers in rats with chronic heart failure.

Puerarin upregulates PPAR α and its downstream target genes in myocardial cells in a rat chronic heart failure model. PPAR α and its downstream target gene expression levels were analyzed in rat myocardial cells. Puerarin increased PPAR α




Figure 3. Puerarin inhibits myocardial apoptosis and inflammation in rats with chronic heart failure. (A) The percentage of TUNEL-positive cells in myocardial tissue was reduced in the puerarin group compared with the PBS group. (B) Expression of GLUT4 and CD36 in myocardial tissues. Serum levels of (C) BNP and troponin T, (D) CRP and (E) creatinine were reduced in rats with chronic heart failure treated with puerarin compared with the PBS group. * $P < 0.05$ and ** $P < 0.01$ vs. PBS. GLUT4, glucose transporter type 4; ns, not significant; CRP, c reactive protein.

and its downstream target Nrf1, Fos and Yy1 gene and protein expression levels in myocardial cells from rats with chronic heart failure compared with control (Fig. 5A and B, $P < 0.01$). Puerarin also upregulated the expression of PPAR α downstream target genes ACC1, FAS, L-PK and MCAD compared with the control group (Fig. 5C and D, $P < 0.01$). These results indicated that puerarin may upregulate PPAR α and its downstream target genes in myocardial cells from rats with chronic heart failure.

Puerarin suppresses apoptosis and inflammation in myocardial cells. The anti-inflammatory and antiapoptotic efficacy of puerarin was further analyzed in myocardial cells *in vitro*. Puerarin significantly decreased TNF- α , IL-1 β and IL-6 expression in myocardial cells compared with control group (Fig. 6A, $P < 0.01$). In addition, puerarin attenuated apoptosis of myocardial cells compared with the control group (Fig. 6B, $P < 0.01$). These results indicated that puerarin may have anti-inflammatory and antiapoptotic efficacy in myocardial cells.

Puerarin inhibits apoptosis and inflammation in myocardial cells via the PPAR α pathway. The potential mechanism of puerarin activity was analyzed in myocardial cells. The results

demonstrated that transfection with si-PPAR α decreased the expression level of PPAR α and its downstream targets, including Nrf1, Fos and Yy1 compared with the si-mimic group (Fig. 7A; $P < 0.01$). Western blotting results revealed that knockdown of PPAR α increased the protein expression of inflammatory factors TNF- α , IL-1 β and IL-6 in myocardial cells compared with the si-mimic group; this effect was reversed in myocardial cells treated with puerarin (Fig. 7B; $P < 0.01$). TUNEL assay demonstrated that treatment with puerarin reversed the effect of PPAR α knockdown on apoptosis of myocardial cells isolated from experimental rats (Fig. 7C; $P < 0.05$). These results suggested that puerarin may inhibit apoptosis and inflammation in myocardial cells via the PPAR α pathway in rats with chronic heart failure.

Discussion

Previous reports have indicated that the mortality rate of patients with chronic heart failure is increasing and suggested that improving the treatment of chronic heart failure may contribute the survival of patients (33-35). The present study aimed to determine whether puerarin treatment exhibits therapeutic efficacy in rats with chronic heart failure. The results of the present study demonstrated that puerarin treatment




Figure 4. Puerarin inhibits inflammation in a rat chronic heart failure model. Puerarin treatment reduced (A) serum and (B) myocardial tissue levels of TNF- α , IL-1 β and IL-6 compared with the PBS group. **P<0.01. TNF α , tumor necrosis factor α ; IL, interleukin; ns, not significant.




Figure 5. Puerarin increases the expression levels of PPAR α and its downstream target genes in cardiac cells from rat models of chronic heart failure. Effects of puerarin on PPAR α , Nrf1, Fos and Yy1 (A) mRNA and (B) protein expression in myocardial cells. Effects of puerarin on (C) gene and (D) protein expression levels of ACC1, FAS, L-PK and MCAD. **P<0.01 vs. control. PPAR α , peroxisome proliferator-activated receptor α ; Nrf1, nuclear respiratory factor 1; Fos, FOS proto-oncogene; Yy1, YY1 transcription factor; ACC1, acetyl-coenzyme A carboxylase α ; FAS, Fas cell surface death receptor; L-PK, L-type pyruvate kinase; MCAD, acetyl-coenzyme A dehydrogenase medium chain.




Figure 6. Puerarin inhibits apoptosis and inflammation in myocardial cells. (A) Puerarin treatment downregulated the expression of inflammatory factors TNF-α, IL-1β and IL-6 in myocardial cells. (B) Puerarin attenuated apoptosis in myocardial cells. **P<0.01 vs. control. TNFα, tumor necrosis factor α; IL, interleukin.




Figure 7. Puerarin reverses the pro-apoptotic and pro-inflammatory effects of PPARα knockdown. (A) Effects of PPARα knockdown on the expression levels of PPARα and its downstream target proteins Nrf1, Fos and Yy1 in myocardial cells. (B) Effects of PPARα knockdown on the expression levels of inflammatory factors TNF-α, IL-1β and IL-6 in myocardial cells in the presence or absence of puerarin. (C) Effects of PPARα knockdown and puerarin treatment on apoptosis of myocardial cells. *P<0.05 and **P<0.01 as indicated. PPARα, peroxisome proliferator-activated receptor α; Nrf1, nuclear respiratory factor 1; Fos, FOS proto-oncogene; Yy1, YY1 transcription factor; si-PPARα, small interfering RNA targeting PPARα; si-mimic, control small interfering RNA; TNFα, tumor necrosis factor α; IL, interleukin; ns, not significant.

significantly improved cardiac function and increased body weight during a 4-week treatment following chronic heart failure model induction. In addition, the levels of inflammatory markers TNF- α , IL-1 β and IL-6 were reduced by puerarin compared with PBS treatment in rats. Puerarin increased the expression of PPAR α and its downstream target genes GLUT4 and CD36 compared with PBS treatment, which are involved in the cardiac metabolism (36). The results of the present study also demonstrated that puerarin decreased LDH and SDH levels in rats with chronic heart failure compared with PBS.

Increases in TNF- α levels may contribute to the progression of cardiac remodeling and decompensated heart failure (37). TNF- α , IL-1 β and IL-6 are the major pro-inflammatory markers identified as contributors to chronic heart failure (38). The results of the present study demonstrated that puerarin decreased serum levels of TNF- α , IL-1 β and IL-6 in a rat chronic heart failure model. However, the prognostic value of inflammatory markers TNF- α , IL-1 β and IL-6 requires further analysis in patients with chronic heart failure.

Changes in the myocardial activities of LDH and SDH in the experimental models of diabetic and post-infarction damage are parameters used in evaluating abnormal processes of glycolysis and oxidative phosphorylation in rat cardiac mitochondria (39). A previous study has indicated that decreasing the creatine kinase-MB and LDH levels protected the heart against ischemia-reperfusion injury (40). The results of the present study revealed that puerarin attenuated serum LDH and SDH levels in rats with chronic heart failure, which may be one of mechanisms by which puerarin significantly increased the survival rate and improved cardiac function of experimental rats. Additionally, a previous study has reported that puerarin improved cardiac function through regulation of energy metabolism in streptozotocin-nicotinamide induced diabetic mice following myocardial infarction (41). The present study demonstrated that puerarin significantly improved FS, EF, CO and HR compared with PBS-treated in rats with chronic heart failure.

Acute myocardial infarction increases cardiac GLUT4 levels and partially preserves heart function in spontaneously hypertensive rats (42). CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart, and the coronary vasoconstrictive response correlates with CD36 expression levels (43). The present study demonstrated that puerarin treatment increased the expression levels of GLUT4 and decreased the expression levels of CD36. PPARs are nuclear hormone receptors that regulate genes involved in energy metabolism and inflammation (44). The results of the present study revealed that puerarin increased the expression of downstream target genes of PPAR α involved in a range of metabolic pathways, including Nrf1, Fos, Yy1, ACC1, FAS, L-PK and MCAD, which enhance metabolic plasticity of skeletal muscles (45). In addition, puerarin increased the body weight of rats with chronic heart failure, which indicated that puerarin may regulate energy metabolism in myocardial cells; however, this requires further investigation. The results of the present study demonstrated that puerarin reversed the pro-apoptotic and pro-inflammatory effects of PPAR α knockdown in myocardial cells, which suggested that puerarin

inhibited apoptosis and inflammation in myocardial cells via the PPAR α pathway.

In conclusion, the results of the present study indicated that puerarin exhibited ameliorative properties on myocardial function in a rat chronic heart failure model through the regulation of myocardial cell apoptosis. The results revealed that decreased LDH and SDH levels, as well as decreased expression levels of inflammatory markers, including TNF- α , IL-1 β and IL-6, were identified in puerarin-treated rats with chronic heart failure. These data suggest that puerarin may be a promising agent for therapeutic intervention in treating chronic heart failure.

Acknowledgements

Not applicable.

Funding

This study was supported by the Science and Technology Fund of Tianjin Municipal Commission of Health and Family Planning, Tianjin, China (grant no. 2015KY32) and the Science and Technology Fund of Tianjin Chest Hospital, Tianjin, China (grant no. 2018XKZ06).

Availability of data and materials

The analyzed datasets generated during the study are available from the corresponding author on reasonable request.

Authors' contributions

LH and TW performed the experiments. BWC and FML prepared and analyzed experimental data. JX designed the study.

Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Tianjin Chest Hospital.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Wang Y, Li X, Li Z, Zhang Y and Wang D: YiQiFuMai injection for chronic heart failure: Protocol for a systematic review and meta-analysis. *Medicine (Baltimore)* 97: e9957, 2018.
2. Taylor KS, Verbakel JY, Feakins BG, Price CP, Perera R, Bankhead C and Plüddemann A: Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: Systematic review and meta-analysis. *BMJ* 361: k1450, 2018.
3. Neubauer S, Zeidler J, Schilling T, Engel S, Linder R, Verheyen F, Haverich A and von der Schulenburg JG: Suitability and usability of claims data for review of guidelines for the treatment of chronic heart failure. *Gesundheitswesen* 78: e135-e144, 2016.

4. McCormack PL: Sacubitril/valsartan: A review in chronic heart failure with reduced ejection fraction. *Drugs* 76: 387-396, 2016.
5. Carvalho VO: Aerobic exercise prescription in patients with chronic heart failure: A review in the beta-blocker era. *J Cardiovasc Med (Hagerstown)* 13: 570-574, 2012.
6. Augustin U and Henschke C: Does telemonitoring lead to health and economic benefits in patients with chronic heart failure? -a systematic review. *Gesundheitswesen* 74: e114-121, 2012 (In German).
7. Zhang X, Ma LL, Yao DK and Wang LX: Prediction values of T wave alternans for sudden cardiac death in patients with chronic heart failure: A brief review. *Congest Heart Fail* 17: 152-156, 2011.
8. Antoniadis AP, Sieniewicz B, Gould J, Porter B, Webb J, Claridge S, Behar JM and Rinaldi CA: Updates in cardiac resynchronization therapy for chronic heart failure: Review of multisite pacing. *Curr Heart Fail Rep* 14: 376-383, 2017.
9. Antoniadis AP, Sieniewicz B, Gould J, Porter B, Webb J, Claridge S, Behar JM and Rinaldi CA: Erratum to: Updates in cardiac resynchronization therapy for chronic heart failure: Review of multisite pacing. *Curr Heart Fail Rep* 14: 384, 2017.
10. Health Quality Ontario: Effect of early follow-up after hospital discharge on outcomes in patients with heart failure or chronic obstructive pulmonary disease: A systematic review. *Ont Health Technol Assess Ser* 17: 1-37, 2017.
11. Wang W, Jiang T, Li C, Chen J, Cao K, Qi LW, Li P, Zhu W, Zhu B and Chen Y: Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. *J Thorac Dis* 8: E269-E277, 2016.
12. Vongmany J, Hickman LD, Lewis J, Newton PJ and Phillips JL: Anxiety in chronic heart failure and the risk of increased hospitalisations and mortality: A systematic review. *Eur J Cardiovasc Nurs* 15: 478-485, 2016.
13. Siouta N, van Beek K, Preston N, Hasselaar J, Hughes S, Payne S, Garralda E, Centeno C, van der Eerden M, Groot M, *et al*: Towards integration of palliative care in patients with chronic heart failure and chronic obstructive pulmonary disease: A systematic literature review of European guidelines and pathways. *BMC Palliat Care* 15: 18, 2016.
14. Webb N, Cowie MR, Taylor M, Briggs A, Cohen A, de Pourville G, Haroun R, Trueman D and Deschaseaux C: The cost-effectiveness of treatment for chronic heart failure: A systematic review. *Value Health* 18: A391, 2015.
15. Kane PM, Murtagh FE, Ryan K, Mahon NG, McAdam B, McQuillan R, Ellis-Smith C, Tracey C, Howley C, Raleigh C, *et al*: The gap between policy and practice: A systematic review of patient-centred care interventions in chronic heart failure. *Heart Fail Rev* 20: 673-687, 2015.
16. Macdonald PS: Combined angiotensin receptor/neprilysin inhibitors: A review of the new paradigm in the management of chronic heart failure. *Clin Ther* 37: 2199-2205, 2015.
17. Shochat MK, Shotan A, Blondheim DS, Kazatsker M, Dahan I, Asif A, Rozenman Y, Kleiner I, Weinstein JM, Frimerman A, *et al*: Non-invasive lung IMPEDANCE-guided preemptive treatment in chronic heart failure patients: A randomized controlled trial (IMPEDANCE-HF Trial). *J Card Fail* 22: 713-722, 2016.
18. Kervadec A, Bellamy V, El Harane N, Arakelian L, Vanneaux V, Cacciapuoti I, Nemetalla H, Périer MC, Toeg HD, Richart A, *et al*: Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. *J Heart Lung Transplant* 35: 795-807, 2016.
19. Markgren R, Brännström M, Lundgren C and Boman K: Impacts of person-centred integrated chronic heart failure and palliative home care on pharmacological heart failure treatment: A substudy of a randomised trial. *BMJ Support Palliat Care* 9: e10, 2016.
20. Zhang H, Liu Y, Lao M, Ma Z and Yi X: Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. *Exp Gerontol* 46: 30-37, 2011.
21. Zhu G, Wang X, Chen Y, Yang S, Cheng H, Wang N and Li Q: Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease. *Planta Med* 76: 1820-1826, 2010.
22. Qin F, Huang X, Zhang HM and Ren P: Pharmacokinetic comparison of puerarin after oral administration of Jiawei-Xiaoyao-San to healthy volunteers and patients with functional dyspepsia: Influence of disease state. *J Pharm Pharmacol* 61: 125-129, 2009.
23. Duan S, Li YF and Luo XL: Effect of puerarin on heart function and serum oxidized-LDL in the patients with chronic cardiac failure. *Hunan Yi Ke Da Xue Xue Bao* 25: 176-178, 2000 (In Chinese).
24. He H, Shi M, Yang J, Zeng X, Qiao H, Wu L and Li L: The correlation between angiogenesis and abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure, and improvement by puerarin. *Phytother Res* 22: 948-956, 2008.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
26. Liu B, Zhao C, Li H, Chen X, Ding Y and Xu S: Puerarin protects against heart failure induced by pressure overload through mitigation of ferroptosis. *Biochem Biophys Res Commun* 497: 233-240, 2018.
27. Zhirov IV, Zaseeva AV, Masenko VP and Tereshchenko SN: Peroxisome proliferator-activated receptors-alpha (PPAR-alpha) and chronic heart failure: Is there a reason to discuss the metabolic strategy of treatment? *Ter Arkh* 86: 78-82, 2014 (In Russian).
28. Fu YH, Lin QX, Li XH, Fei HW, Shan ZX, Huang XZ, Liu XY, Yang M, Lin SG, Zhou SF, *et al*: A novel rat model of chronic heart failure following myocardial infarction. *Methods Find Exp Clin Pharmacol* 31: 367-373, 2009.
29. Zhao W, Liu L, Wang Y, Mao T and Li J: Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. *Exp Ther Med* 11: 183-190, 2016.
30. Kirk RGW: Recovering the principles of humane experimental technique: The 3Rs and the human essence of animal research. *Sci Technol Human Values* 43: 622-648, 2018.
31. Dergilev KV, Tsokolaeva ZI, Rubina KA, Sysoeva VY, Makarevich PI, Boldyreva MA, Beloglazova IB, Zubkova ES, Sharonov GV, Akchurin RS and Parfyonova YV: Isolation and characterization of cardiac progenitor cells obtaining from myocardial right atrial appendage tissue. *Tsitologiya* 58: 340-348, 2016 (In English, Russian).
32. Sun WP, Lu YX, Zhang XY, Tang WW and Huang QY: Effects of cocaine on activities of ATPase, LDH and SDH in mouse splenocytes. *Fa Yi Xue Za Zhi* 26: 81-83, 2010 (In Chinese).
33. Lin MH, Yuan WL, Huang TC, Zhang HF, Mai JT and Wang JF: Clinical effectiveness of telemedicine for chronic heart failure: A systematic review and meta-analysis. *J Investig Med* 65: 899-911, 2017.
34. Yohannes AM, Chen W, Moga AM, Leroi I and Connolly MJ: Cognitive impairment in chronic obstructive pulmonary disease and chronic heart failure: A systematic review and meta-analysis of observational studies. *J Am Med Dir Assoc* 18: 451 e451-451 e411, 2017.
35. Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, Wang X, Tang S, Nagi A, Kosinski AS and Williams JW Jr: Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: A systematic review. *Ann Intern Med* 166: 191-200, 2017.
36. Heather LC, Pates KM, Atherton HJ, Cole MA, Ball DR, Evans RD, Glatz JF, Luiken JJ, Griffin JL and Clarke K: Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion. *Circ Heart Fail* 6: 1058-1066, 2013.
37. Tziakas D, Chalikias G, Parissis JT, Hatzinikolaou H, Stakos D, Papadopoulos E, Kortsaris A and Hatzeras D: Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3. *Eur Cytokine Netw* 15: 231-239, 2004.
38. Adamopoulos S, Parissis JT and Kremastinos DT: A glossary of circulating cytokines in chronic heart failure. *Eur J Heart Fail* 3: 517-526, 2001.
39. Afanasiev SA, Egorova MV, Kondratyeva DS, Batalov RE and Popov SV: Comparative analysis of changes of myocardial angiogenesis and energy metabolism in postinfarction and diabetic damage of rat heart. *J Diabetes Res* 2014: 827896, 2014.
40. Amani M, Jeddi S, Ahmadiasl N, Usefzade N and Zaman J: Effect of HEMADO on level of CK-MB and LDH enzymes after ischemia/reperfusion injury in isolated rat heart. *Bioimpacts* 3: 101-104, 2013.

41. Cheng W, Wu P, Du Y, Wang Y, Zhou N, Ge Y and Yang Z: Puerarin improves cardiac function through regulation of energy metabolism in Streptozotocin-Nicotinamide induced diabetic mice after myocardial infarction. *Biochem Biophys Res Commun* 463: 1108-1114, 2015.
42. Schaun MI, Marschner RA, Peres TR, Markoski MM and Lehnen AM: Aerobic training prior to myocardial infarction increases cardiac GLUT4 and partially preserves heart function in spontaneously hypertensive rats. *Appl Physiol Nutr Metab* 42: 334-337, 2017.
43. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D and Ong H: CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. *Circ Res* 90: 844-849, 2002.
44. Haemmerle G, Moustafa T, Woelkart G, Büttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, *et al*: ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- α and PGC-1. *Nat Med* 17: 1076-1085, 2011.
45. Muoio DM, MacLean PS, Lang DB, Li S, Houmard JA, Way JM, Winegar DA, Corton JC, Dohm GL and Kraus WE: Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) alpha knock-out mice. Evidence for compensatory regulation by PPAR delta. *J Biol Chem* 277: 26089-26097, 2002.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

RETRACTED